EU agency rejects Sanofi, Isis cholesterol drug
LONDON (Reuters) - European regulators on Friday recommended against approval of Sanofi and Isis Pharmaceutical's drug Kynamro for treatment of a rare genetic disorder that causes unusually high cholesterol.
The European Medicines Agency said it was concerned about the medicine's safety, noting that a high proportion of patients stopped taking it within two years, mainly due to side effects such as flu-like symptoms, injection site reactions and liver toxicity.
The European rebuff contrasts with a green light for the drug, known generically as mipomersen, by a U.S. advisory panel in October.
Sanofi's Genzyme unit said it was disappointed by the decision and planned to request a re-examination.
(Reporting by Ben Hirschler)
- India trims perks for U.S. staff in dispute over envoy's New York arrest
- Washington, DC city council raises minimum wage to $11.50/hr in 2016
- China confirms near miss with U.S. ship in South China Sea
- Mega Millions lottery winning tickets sold in California, Georgia |
- The Fabulously Entrepreneurial Life of Ronnie Biggs
During Soviet times, Sochi gained a reputation for tolerance but the city's once vibrant gay scene has been shrinking as Russia prepares to host the 2014 Winter Games. Slideshow